Cellectar Biosciences, Inc. — Director's Dealing 2021

Mar 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2021-03-04

Reporting Person: CARUSO JAMES V (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Common Stock	P	5100	$1.6978	Acquired	86401	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-04	Stock option (right to buy)	$1.74	A	1600000	Acquired	2031-03-04	Common Stock (1600000)	Direct
2021-03-04	Series A Warrants	$30.40	S	46948	Acquired	2021-04-20	Common Stock (4694)	Direct

Footnotes

F1: Mr. Caruso used the proceeds of the sale of the Series A Warrants, which expire in April 2021, to purchase shares of Cellectar's common stock.

F2: Ten warrants are convertible into one share of Cellectar's common stock at an exercise price of $30.40 per share of common stock.

F3: This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.